… The indication of afatinib and erlotinib for SqCC of the lung had not been approved.
However, because the oncologist and patients would still pursue these agents as second-line …

… erlotinib therapy may be most beneficial in patients with good response to first-line erlotinib,
… In brief, it is conceivable that patients with slow PD could benefit from continuation of EGFR …

… in the comparison of erlotinib and chemotherapy in patients with non-small-cell lung cancer.
… survival for erlotinib versus chemotherapy in the second-line setting. Patients classified as …

… Our study retrospectively enrolled patients who had received gefitinib, erlotinib or afatinib
for first-line treatment of stage IV or post-operative recurrent (advanced) NSCLC between 2014/…

… ,2 the potential economic impact of erlotinib use in the 60% of treated patients who develop
rash is … of erlotinib versus placebo overall and within a predefined subgroup of patients who …

… phase II trial of second- or third-line erlotinib treatment in elderly patients with NSCLC. The
primary endpoint was overall response rate (ORR) and the secondary endpoints were PFS, …

… erlotinib metabolism versus non-smoking patients, which reduces exposure. Therefore, an
increased erlotinib … and safety of 300 mg erlotinib (E300) as second-line therapy in current …

… , some patient's performance status improved noticeably and rapidly after erlotinib therapy.
… the use of first-line erlotinib therapy, even in patients having favorable molecular predictors …

… patients benefit from EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, whereas
their role in the treatment of patients … to optimize second-line treatment in NSCLC patients …

… In the current study, ∼40% of erlotinib-treated patients in the overall population and exon
19 deletion subpopulation did not receive any post-study treatment. On the other hand, almost …